Parameter | Odds ratio | 95% CI | P | P multivariate analysis |
Activity (MBq)/weight (kg) | 0.989 | 0.944–1.035 | 0.62 | |
Abiretarone | 0.846 | 0.368–1.944 | 0.69 | |
Enzalutamide | 0.932 | 0.398–2.181 | 0.87 | |
Chemotherapy | 0.828 | 0.426–1.609 | 0.57 | |
223Ra | 0.436 | 0.097–1.958 | 0.27 | |
Bisphosphonate or denosumab | 0.848 | 0.231–3.109 | 0.80 | |
No. of bone metastases | 1.165 | 0.444–3.061 | 0.75 | |
Extent of lymph node metastases | 1.281 | 0.731–2.243 | 0.38 | |
Existence of liver metastases | 1.114 | 0.202–6.158 | 0.90 | |
ECOG performance status | 1.685 | 0.761–3.733 | 0.19 | |
Albumin | 0.987 | 0.847–1.149 | 0.86 | |
AST | 1.018 | 0.988–1.048 | 0.23 | |
ALT | 1.043 | 0.976–1.115 | 0.21 | |
GGT | 1.024 | 1.006–1.041 | 0.008 | NS |
ALP | 1.003 | 0.999–1.006 | 0.15 | |
LDH | 1.002 | 1.000–1.005 | 0.04 | NS |
Creatinine | 4.714 | 0.464–47.907 | 0.19 | |
Total bilirubin | 0.014 | <0.001–7.401 | 0.18 | |
Hb | 0.574 | 0.341–0.967 | 0.04 | NS |
RBC | 0.429 | 0.127–1.444 | 0.17 | |
WBCs | 1.220 | 0.890–1.674 | 0.21 | |
PSA level | 0.999 | 0.997–1.000 | 0.15 | |
SUVmax (bone) | 0.974 | 0.931–1.020 | 0.26 | |
SUVmax (lymph node) | 0.980 | 0.944–1.018 | 0.30 | |
SUVmax bone/liver | 0.746 | 0.529–1.053 | 0.09 | |
SUVmax bone/spleen | 0.635 | 0.394–1.022 | 0.06 | |
SUVmax lymph node/liver | 0.752 | 0.501–1.130 | 0.16 | |
SUVmax lymph node/spleen | 0.828 | 0.612–1.120 | 0.22 | |
Plt | 1.010 | 1.001–1.018 | 0.02 | 0.01 |
CRP | 1.047 | 1.011–1.085 | 0.009 | NS |
Age | 0.885 | 0.805–0.972 | 0.01 | NS |
Gleason score | 4.121 | 1.304–13.016 | 0.01 | NS |
Regular need for pain medication | 0.091 | 0.017–0.501 | 0.005 | 0.0018 |
CI = confidence interval; NS = not significant; AST = aspartate aminotransferase; ALT = alanine transaminase; ALP = alkaline phosphatase; LDH = lactate dehydrogenase; Hb = hemoglobin; RBC = red blood cells; WBCs = white blood cells; Plt = platelets.